Lidocaine 2% Fresenius Kabi

Lidocaine, the active ingredient in Lidocaine 2% Fresenius Kabi, is a local anesthetic presented as a 2% solution for injection for epidural, intramuscular, and intravenous use. It provides rapid, reversible loss of sensation and pain relief in a variety of clinical procedures. GNH USA supplies Lidocaine 2% Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine is a local anesthetic used to block nerve conduction for procedural and postoperative pain management.

Local anesthesia: provides rapid onset numbness for minor surgical or diagnostic procedures. Epidural analgesia: delivers analgesia during labor, surgery, or postoperative period. Regional nerve block: facilitates targeted pain control for limb or trunk surgeries. Dental procedures: numbs oral tissues for dental work.

Lidocaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Transient burning or stinging at the injection site - Mild dizziness or light‑headedness - Nausea or vomiting - Tinnitus (ringing in the ears)

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia - Central nervous system seizures - Methemoglobinemia leading to cyanosis - Severe allergic reactions such as anaphylaxis

When using Lidocaine 2% solution, clinicians should observe several safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid rapid high‑dose administration in patients with conduction disorders. - CNS disorders: use cautiously in patients with a history of seizures. - Pregnancy: consider risk‑benefit; data are limited. - Elderly or hepatic impairment: dose may need adjustment. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - Beta‑blockers: increase risk of bradycardia and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lidocaine plasma levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase bleeding risk. - General anesthetics (e.g., propofol): additive CNS depression. - Other local anesthetics: cumulative toxicity risk.